Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer.
Saved in:
| Title: | Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer. |
|---|---|
| Authors: | Chan, Conrad1 (AUTHOR), Prozzo, Vanessa1 (AUTHOR), Aghevlian, Sadaf1 (AUTHOR), Reilly, Raymond M.1,2,3,4 (AUTHOR) raymond.reilly@utoronto.ca |
| Source: | EJNMMI Radiopharmacy & Chemistry. 12/21/2022, Vol. 7 Issue 1, p1-21. 21p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
